chikungunya virus Archives
Chikungunya antibody identified at VUMC moves forward
Mar. 4, 2021—Evotec, a drug company headquartered in Hamburg, Germany, has begun a phase 1 clinical trial of a monoclonal antibody against the chikungunya virus that was identified at Vanderbilt University Medical Center.
Early effort to thwart chikungunya infection shows positive results
Sep. 13, 2019—Phase 1 trial results in new approach to combat the chikungunya
New method tested to block chikungunya infection
Jun. 14, 2019—Scientists are testing a new way to fight chikungunya virus that involves injecting genetic material into the bodies of infected and at-risk individuals to trigger rapid production of potent, virus-neutralizing antibodies.
VUMC chikungunya antibody set to enter clinical trial
Feb. 21, 2019—A monoclonal antibody against the chikungunya virus developed by researchers at Vanderbilt University Medical Center is the first monoclonal antibody encoded by messenger RNA to enter a clinical trial.
Alphavirus “Achilles heel”
May. 17, 2018—Targeting the protein that mosquito-borne viruses use to enter cells could be a strategy for preventing infection by multiple emerging viruses.
VUMC joins national effort to block global pandemics of potentially lethal viruses
Jan. 11, 2018—The U.S. Defense Advanced Research Projects Agency (DARPA) has signed a five-year cooperative agreement worth up to $28 million with Vanderbilt University Medical Center (VUMC) to develop methods for preventing the global spread of viruses like chikungunya and Zika.
Keep your coat on, virus!
Sep. 22, 2015—A compound acting on serotonin receptors delays a critical step during reovirus cell entry, reducing viral infectivity.
Vanderbilt researchers develop potential treatment to fight mosquito-borne chikungunya virus
Jul. 8, 2015—In late 2013 the Caribbean had its first case of the mosquito-borne chikungunya virus. Today there have been almost 1.2 million cases in 44 countries or territories, including 177 cases in 31 U.S. States.